Similar articles for PMID: 18434935

Year	Number of Results
1957	1
1965	1
1969	1
1988	1
1997	1
1998	1
1999	4
2000	9
2001	7
2002	13
2003	14
2004	20
2005	14
2006	18
2007	26
2008	34
2009	30
2010	12
2011	3
2012	4
2013	6
2014	8
2015	3
2016	8
2017	12
2018	4
2019	4
2020	1
2021	4
2023	1
2024	0

1

Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.

Speer ME, Fernandes CJ, Boron M, Groothuis JR. Speer ME, et al. Pediatr Infect Dis J. 2008 Jun;27(6):559-61. doi: 10.1097/INF.0b013e3181673c15. Pediatr Infect Dis J. 2008. PMID: 18434935

2

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S. Giebels K, et al. Pediatr Pulmonol. 2008 Feb;43(2):169-74. doi: 10.1002/ppul.20751. Pediatr Pulmonol. 2008. PMID: 18085710

3

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.

Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Frogel M, et al. J Perinatol. 2008 Jul;28(7):511-7. doi: 10.1038/jp.2008.28. Epub 2008 Mar 27. J Perinatol. 2008. PMID: 18368063

4

Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.

Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J; Palivizumab Outcomes Registry Group. Frogel M, et al. Pediatr Infect Dis J. 2008 Oct;27(10):870-3. doi: 10.1097/INF.0b013e318174e0c4. Pediatr Infect Dis J. 2008. PMID: 18776822

5

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.

Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, Calcagno JA, Eki C, Harris KA, Joyave J, McFarland K, Protter P, Sullivan M, Stanford A, Lovett N, Ortiz M, Rojas S, Cyrus S, Cyrus J, Cohen S, Buchin D, Riordan L, Zuniga M, Shah R, Minard C, Quintin A, Douglas G, van Houten J, Freutner S, Chartrand S, Nowatzke P, Romero J, Rhodes T, Benoit M, Walter E, Walker L, DeBonnett L, Cross M, Free T, Martin S, Shank K, Guedes B, Atkinson LA, Halpin GJ, Rouse K, Hand I, Geiss D, Marshall JR, Burleson L, Boland J, Seybold K, Hunter V, Unfer S, Schmucker J, Gley M, Marcus M, Thompson P, Milla P, Young C, Zanni R, Zinno V, Fetter-Zarzeka A, Busey A, Sokunbi MA, Airington S, Richard N, Muraligopal V, Lewis S, Weber FT, Giordano BP, Linehan D, Roach J, Davis R, Rzepka AA, Booth T, Smeltzer D, Walsh J, Arispe E, Rowley R, Bolling C, Botts T, Haskett K, Raby D, Batiz E, Gelfand A, Farrell L, Butler S, Colby L, Schochet P, Bentler J, Hirsch D, Wilkinson L, Aaronson A, Bennett E, Wingate J, Quinn D, Komendowski K, Deckard M, Frogel M, Nerwen C, Copenhaver S, Prater M, Wolsztein J, Mackey K, Benbow M, Naranjo M, Hensley S, Hayes C, Sadeghi … See abstract for full author list ➔ Parnes C, et al. Pediatr Pulmonol. 2003 Jun;35(6):484-9. doi: 10.1002/ppul.10288. Pediatr Pulmonol. 2003. PMID: 12746948

6

Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?

Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC. Geskey JM, et al. Clin Ther. 2004 Dec;26(12):2130-7. doi: 10.1016/j.clinthera.2004.12.005. Clin Ther. 2004. PMID: 15823776 Review.

7

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group. Pedraz C, et al. Pediatr Infect Dis J. 2003 Sep;22(9):823-7. doi: 10.1097/01.inf.0000086403.50417.7c. Pediatr Infect Dis J. 2003. PMID: 14506376

8

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.

Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL; Palivizumab Long-Term Respiratory Outcomes Study Group. Simoes EA, et al. J Pediatr. 2007 Jul;151(1):34-42, 42.e1. doi: 10.1016/j.jpeds.2007.02.032. J Pediatr. 2007. PMID: 17586188 Clinical Trial.

9

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A. Wegner S, et al. Pediatrics. 2004 Dec;114(6):1612-9. doi: 10.1542/peds.2004-0959. Pediatrics. 2004. PMID: 15574623

10

[Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].

Scholz H. Scholz H. Z Geburtshilfe Neonatol. 2000 May-Jun;204(3):120-2. doi: 10.1055/s-2000-10208. Z Geburtshilfe Neonatol. 2000. PMID: 10909169 Clinical Trial. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

251 results

Results by year